Condition: Hodgkin Lymphoma, Adult · Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin's Lymphoma, Followed by Brentuximab Vedotin Consolidation (instead of Autologous Hematopoietic Stem Cell Transplantation) in Those who Attained a Metabolic Complete Remission after Salvage Therapy
This description comes directly from the study's public registry record.
lucia palacios, MSc · +18599134526 · ensayosclinicos01@geltamo.com
Angel Cedillo, MSc · +34 91315780 · sc@geltamo.com
Always discuss trial participation with your own doctor first.
| Institut Català D'Oncologia - Hospital Germans Trias I Pujol | Barcelona, Barceolna, Spain | Recruiting |
| Hospital Universitario Marqués de Valdecilla | Santander, Cantabria, Spain | Recruiting |
| Hospital Universitario Central de Asturias | Oviedo, Principality of Asturias, Spain | Recruiting |
| Complexo Hospitalario Universitario A Coruña | A Coruña, Spain | Recruiting |
| Hospital Clínic de Barcelona | Barcelona, Spain | Recruiting |
| Hospital de La Santa Creu I Sant Pau | Barcelona, Spain | Recruiting |
| Institut Català D'Oncologia - Hospital Duran I Reynals | Barcelona, Spain | Recruiting |
| Institut Català D'Oncologia | Barcelona, Spain | Recruiting |
| Hospital Universitario de Cruces | Bilbao, Spain | Recruiting |
| Hospital Universitario Virgen de Las Nieves | Granada, Spain | Recruiting |
| Hospital General Universitario Gregorio Marañón | Madrid, Spain | Recruiting |
| Hospital Ramón Y Cajal | Madrid, Spain | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04378647